GlaxoSmithKline plc Company Profile (LON:GSK)

About GlaxoSmithKline plc (LON:GSK)

GlaxoSmithKline plc logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: LON:GSK
  • CUSIP: N/A
  • Web:
  • Market Cap: £71.07 billion
  • Outstanding Shares: 4,888,000,000
Average Prices:
  • 50 Day Moving Avg: GBX 1,503.38
  • 200 Day Moving Avg: GBX 1,606.97
  • 52 Week Range: GBX 1,444 - GBX 1,745.56
  • Trailing P/E Ratio: 37.19
  • P/E Growth: 2.24
Sales & Book Value:
  • Annual Revenue: £29.83 billion
  • Price / Sales: 2.38
  • Book Value: GBX 0.17 per share
  • Price / Book: 85.53
  • Dividend Yield: 5.1%
  • EBIDTA: £8.15 billion
  • Net Margins: -1.17%
  • Return on Equity: -57.19%
  • Return on Assets: -0.59%
  • Average Volume: 6.81 million shs.

Frequently Asked Questions for GlaxoSmithKline plc (LON:GSK)

What is GlaxoSmithKline plc's stock symbol?

GlaxoSmithKline plc trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

How often does GlaxoSmithKline plc pay dividends? What is the dividend yield for GlaxoSmithKline plc?

GlaxoSmithKline plc announced a dividend on Wednesday, July 26th. Shareholders of record on Thursday, August 10th will be paid a dividend of GBX 19 per share on Thursday, October 12th. This represents a dividend yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th. The official announcement can be seen at this link. View GlaxoSmithKline plc's Dividend History.

Where is GlaxoSmithKline plc's stock going? Where will GlaxoSmithKline plc's stock price be in 2017?

21 analysts have issued twelve-month target prices for GlaxoSmithKline plc's stock. Their forecasts range from GBX 1,300 to GBX 2,000. On average, they expect GlaxoSmithKline plc's stock price to reach GBX 1,703.45 in the next twelve months. View Analyst Ratings for GlaxoSmithKline plc.

Who are some of GlaxoSmithKline plc's key competitors?

Who are GlaxoSmithKline plc's key executives?

GlaxoSmithKline plc's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer - Designate, Executive Director
  • Simon Dingemans, Chief Financial Officer, Executive Director
  • Patrick Vallance, President - Pharmaceuticals R&D, Executive Director
  • Roger Connor, President - Global Manufacturing & Supply
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E Troy, Senior Vice President, General Counsel
  • Claire Thomas, Senior Vice President - Human Resources
  • Nick Hirons, Senior Vice President – Global Ethics and Compliance

How do I buy GlaxoSmithKline plc stock?

Shares of GlaxoSmithKline plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is GlaxoSmithKline plc's stock price today?

One share of GlaxoSmithKline plc stock can currently be purchased for approximately GBX 1,454.

MarketBeat Community Rating for GlaxoSmithKline plc (LON GSK)
Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  476 (Vote Outperform)
Underperform Votes:  1,146 (Vote Underperform)
Total Votes:  1,622
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for GlaxoSmithKline plc (LON:GSK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Sell Ratings, 10 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.14)
Consensus Price Target: GBX 1,703.45

Analysts' Ratings History for GlaxoSmithKline plc (LON:GSK)
DateFirmActionRatingPrice TargetDetails
9/20/2017Shore CapitalReiterated RatingHoldView Rating Details
9/20/2017Deutsche Bank AGReiterated RatingHoldGBX 1,610View Rating Details
9/19/2017Berenberg BankReiterated RatingBuyGBX 1,835View Rating Details
9/19/2017Bryan, Garnier & CoReiterated RatingNeutralGBX 1,710View Rating Details
9/18/2017Jefferies Group LLCLower Price TargetBuyGBX 1,750 -> GBX 1,675View Rating Details
9/13/2017HSBC Holdings plcReiterated RatingBuyGBX 1,970View Rating Details
9/13/2017J P Morgan Chase & CoLower Price TargetNeutralGBX 1,750 -> GBX 1,570View Rating Details
9/8/2017Morgan StanleySet Price TargetSellGBX 1,600View Rating Details
9/8/2017Citigroup Inc.Reiterated RatingNeutralGBX 1,700View Rating Details
9/6/2017BNP ParibasSet Price TargetNeutralGBX 1,620View Rating Details
9/6/2017Credit Suisse GroupLower Price TargetNeutralGBX 1,775 -> GBX 1,725View Rating Details
8/30/2017Liberum CapitalReiterated RatingBuyGBX 1,900View Rating Details
8/8/2017Goldman Sachs Group, Inc. (The)Set Price TargetBuyGBX 1,900View Rating Details
7/27/2017Kepler Capital MarketsReiterated RatingReduceGBX 1,520View Rating Details
7/27/2017Barclays PLCReiterated RatingEqual weightGBX 1,550View Rating Details
7/26/2017S&P GlobalSet Price TargetSellGBX 1,500View Rating Details
7/26/2017InvestecReiterated RatingBuyGBX 1,800View Rating Details
6/1/2017Beaufort SecuritiesBoost Price TargetBuyGBX 1,750 -> GBX 2,000View Rating Details
3/23/2017Societe GeneraleReiterated RatingSellGBX 1,300View Rating Details
10/27/2016NatixisReiterated RatingNeutralGBX 1,750View Rating Details
10/19/2016Sanford C. BernsteinSet Price TargetNeutralGBX 1,834View Rating Details
8/4/2016Independent Research GmbHSet Price TargetNeutralGBX 1,800View Rating Details
7/27/2016S&P Global Inc.Set Price TargetNeutralGBX 1,650View Rating Details
7/7/2016Canaccord GenuityReiterated RatingHoldGBX 1,785View Rating Details
3/10/2016AlphaValueReiterated RatingAddGBX 1,536View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 1,530View Rating Details
1/28/2016Leerink SwannReiterated RatingMarket PerformGBX 1,565View Rating Details
11/17/2015JP Morgan CazenoveReiterated RatingNeutralGBX 1,370View Rating Details
11/6/2015Oddo SecuritiesReiterated RatingReduceGBX 1,360View Rating Details
(Data available from 9/20/2015 forward)


Earnings History for GlaxoSmithKline plc (LON:GSK)
No earnings announcements for this company have been tracked by


Earnings Estimates for GlaxoSmithKline plc (LON:GSK)
Current Year EPS Consensus Estimate: $109.86 EPS


Dividend History by Quarter for GlaxoSmithKline plc (LON GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/26/2017GBX 191.23%8/10/20178/10/201710/12/2017
4/26/2017GBX 191.21%5/11/20175/11/20177/13/2017
2/8/2017GBX 231.47%2/23/20172/23/20174/13/2017
10/26/2016GBX 191.17%11/3/201611/3/20161/12/2017
7/27/2016GBX 191.12%8/11/20168/11/201610/13/2016
4/27/2016GBX 191.28%5/12/20165/12/20167/14/2016
10/28/2015GBX 191.34%11/12/201511/12/20151/14/2016
10/28/2015GBX 201.34%2/18/20162/18/20164/14/2016
7/29/2015GBX 191.38%8/13/20158/13/201510/1/2015
5/6/2015GBX 191.25%5/14/20155/14/20157/9/2015
2/4/2015GBX 231.56%2/19/20152/19/20154/9/2015
10/22/2014GBX 191.37%11/6/201411/6/20141/8/2015
7/23/2014GBX 191.28%8/6/20148/6/201410/2/2014
4/30/2014GBX 191.17%5/14/20145/14/20147/10/2014
2/5/2014GBX 231.36%2/19/20142/19/20144/10/2014
10/23/2013GBX 191.15%11/13/201311/13/20131/9/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for GlaxoSmithKline plc (LON:GSK)
Insider Trades by Quarter for GlaxoSmithKline plc (LON:GSK)
Insider Trades by Quarter for GlaxoSmithKline plc (LON:GSK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/11/2017Dominic RedfernInsiderBuy8GBX 1,501£120.08
8/9/2017Dominic RedfernInsiderBuy8GBX 1,519£121.52
7/26/2017Manvinder Singh BangaInsiderBuy2,267GBX 1,599£36,249.33
7/14/2017Patrick VallanceInsiderBuy861GBX 1,618£13,930.98
7/11/2017Victoria WhyteInsiderBuy8GBX 1,604£128.32
6/20/2017Victoria WhyteInsiderSell4,820GBX 1,693£81,602.60
6/9/2017Simon DingemansInsiderBuy7GBX 1,701£119.07
5/10/2017Patrick VallanceInsiderBuy7GBX 1,615£113.05
4/26/2017Vivienne CoxInsiderBuy335GBX 1,583£5,303.05
4/18/2017Emma WalmsleyInsiderBuy83GBX 1,647£1,367.01
4/13/2017Dominic RedfernInsiderBuy230GBX 1,639£3,769.70
3/9/2017Sir Andrew P WittyInsiderBuy7GBX 1,673£117.11
3/7/2017Moncef SlaouiInsiderBuy56GBX 2,072£1,160.32
2/22/2017Simon DingemansInsiderSell3,589GBX 1,640£58,859.60
2/20/2017Sir Andrew P WittyInsiderSell10,633GBX 1,634£173,743.22
2/16/2017Patrick VallanceInsiderSell32,996GBX 1,624£535,855.04
2/9/2017Victoria WhyteInsiderSell4,820GBX 1,576£75,963.20
2/8/2017Vivienne CoxInsiderBuy342GBX 1,555£5,318.10
1/11/2017Simon DingemansInsiderBuy8GBX 1,596£127.68
1/9/2017Moncef SlaouiInsiderBuy58GBX 1,972£1,143.76
12/9/2016Sir Andrew P WittyInsiderBuy8GBX 1,478£118.24
11/9/2016Victoria WhyteInsiderBuy8GBX 1,593£127.44
11/3/2016Moncef SlaouiInsiderBuy6GBX 1,937£116.22
10/27/2016Sir Andrew P WittyInsiderSell10,000GBX 1,636£163,600
10/26/2016Manvinder Singh BangaInsiderBuy1,750GBX 1,643£28,752.50
10/11/2016Simon DingemansInsiderBuy7GBX 1,728£120.96
10/7/2016Moncef SlaouiInsiderBuy4GBX 2,148GBX 8,592
9/22/2016Moncef SlaouiInsiderBuy2GBX 2,179GBX 4,358
9/9/2016Witty,Sir Andrew PInsiderBuy8GBX 1,616£129.28
8/12/2016Slaoui,MoncefInsiderBuy28GBX 2,208£618.24
8/9/2016Dingemans,SimonInsiderBuy8GBX 1,680£134.40
7/27/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,693£169,300
7/11/2016Witty,Sir Andrew PInsiderBuy7GBX 1,671£116.97
7/8/2016Slaoui,MoncefInsiderBuy4GBX 2,169GBX 8,676
7/1/2016Cartwright,StaceyInsiderBuy461GBX 1,559£7,186.99
6/9/2016Dingemans,SimonInsiderBuy9GBX 1,441£129.69
5/20/2016Slaoui,MoncefInsiderBuy14GBX 2,100£294
5/12/2016Slaoui,MoncefInsiderBuy24GBX 2,103£504.72
5/11/2016Witty,Sir Andrew PInsiderBuy8GBX 1,476£118.08
4/28/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,475£147,500
4/14/2016Slaoui,MoncefInsiderBuy495GBX 2,156£10,672.20
3/31/2016Anderson,Sir RoyInsiderBuy511GBX 1,405£7,179.55
3/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,404£126.36
2/15/2016Dingemans,SimonInsiderSell39,987GBX 1,406£562,217.22
2/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
1/28/2016Dingemans,SimonInsiderBuy684GBX 1,381£9,446.04
1/14/2016Witty,Sir Andrew PInsiderBuy43GBX 1,369£588.67
1/12/2016Dingemans,SimonInsiderBuy9GBX 1,359£122.31
12/9/2015Dingemans,SimonInsiderBuy9GBX 1,325£119.25
11/10/2015Dingemans,SimonInsiderBuy9GBX 1,366£122.94
10/12/2015Dingemans,SimonInsiderBuy10GBX 1,307£130.70
10/1/2015Rohner,UrsInsiderBuy525GBX 1,251£6,567.75
9/10/2015Witty,Sir Andrew PInsiderBuy10GBX 1,318£131.80
8/12/2015Dingemans,SimonInsiderBuy8GBX 1,443£115.44
7/10/2015Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
7/1/2015Wijers,HansInsiderBuy534GBX 13.45GBX 7,182.30
3/31/2015Sir Christopher GentInsiderBuy3,991GBX 1,566£62,499.06
3/9/2015Moncef SlaouiInsiderSell22,274GBX 1,544£343,910.56
2/18/2015Moncef SlaouiInsiderSell1,580GBX 1,553£24,537.40
2/13/2015Simon DingemansInsiderSell12,605GBX 1,543.12£194,510.28
(Data available from 1/1/2013 forward)


Headline Trends for GlaxoSmithKline plc (LON:GSK)
Latest Headlines for GlaxoSmithKline plc (LON:GSK)
DateHeadline logoTheravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva - September 20 at 4:37 PM logoIs GlaxoSmithKline plc (GSK) a Suitable Value Stock? - September 20 at 4:37 PM logoGSK Announces Positive Results From Phase III IMPACT Study Of Trelegy Ellipta - September 20 at 5:21 AM logoGlaxoSmithKline: Results positive in inhaler study - September 20 at 5:21 AM logoInnoviva (INVA) & GlaxoSmithKline Plc (GSK) Granted Approval by FDA for Once-Daily Single Inhaler Triple Therapy ... - - September 20 at 12:18 AM logoGlaxoSmithKline plc's (GSK) "Buy" Rating Reiterated at Berenberg Bank - September 19 at 2:32 PM logoUS FDA Okays GlaxoSmithKline's 3-In-1 Drug Inhaler Trelegy Ellipta - September 19 at 4:49 AM logoFDA Okays GSK's Three-in-one Drug Inhaler For COPD - September 18 at 11:46 PM logoU.S. FDA approves GSK's three-in-one drug inhaler for COPD - September 18 at 11:46 PM logoTheravance Biopharma (TBPH) Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta - September 18 at 6:45 PM logoJefferies Group LLC Reiterates "GBX 1,675" Price Target for GlaxoSmithKline plc (GSK) - September 18 at 6:30 AM logoFDA Nod For NEOS, One Step Closer To EU Approval Are GSK, TSRO, On Watch Is MTFB - September 17 at 11:27 PM logoGlaxoSmithKline plc (GSK) Price Target Cut to GBX 1,570 - September 17 at 6:28 PM logoGlaxoSmithKline plc (GSK) Stock Rating Reaffirmed by HSBC Holdings plc - September 17 at 5:52 PM logoGlaxoSmithKline plc (GSK) Receives Average Rating of "Hold" from Analysts - September 17 at 8:05 AM logoShore Capital Reaffirms "Hold" Rating for GlaxoSmithKline plc (GSK) - September 16 at 11:34 PM logoInnoviva (INVA) & GlaxoSmithKline Plc (GSK) Reports Positive Opinion from EMA CHMP for Trelegy Ellipta Once-Daily ... - - September 15 at 5:58 AM logoFDA Panel Nod For GSK's Shingles Vaccine, FOLD Beyond Essence, FENC Is Red Hot - September 14 at 3:34 AM logoGSK Announces Unanimous FDA Approval For Shingrix In Over 50s - Quick Facts - September 14 at 3:34 AM logoDominic Redfern Buys 8 Shares of GlaxoSmithKline plc (GSK) Stock - September 12 at 1:50 PM logoGlaxoSmithKline plc (GSK) Given a GBX 1,620 Price Target by BNP Paribas Analysts - September 10 at 8:52 PM logoGlaxoSmithKline plc's (GSK) "Neutral" Rating Reiterated at Citigroup Inc. - September 9 at 8:18 PM logoGlaxoSmithKline plc (GSK) PT Set at GBX 1,600 by Morgan Stanley - September 8 at 8:04 PM logoThree Pivotal Phase III Trials To Watch In Biotech - Benzinga - September 7 at 7:27 PM logoGlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy - August 30 at 4:42 PM logoGlaxoSmithKline Dividends Look More Attractive With New Management At The Helm - Seeking Alpha - August 30 at 12:51 AM logoGlaxoSmithKline plc (GSK) Given New GBX 1,750 Price Target at Jefferies Group LLC - August 27 at 8:32 PM logoPerrigo's (PRGO) OTC Version of Nexium Secures FDA Approval - Nasdaq - August 23 at 12:49 AM logo[$$] The questionable strategy of a pharmaceuticals CEO - August 17 at 12:20 AM logoETFs with exposure to GlaxoSmithKline Plc : August 15, 2017 - August 15 at 7:53 PM logoGlaxoSmithKline plc (GSK) Insider Buys £121.52 in Stock - August 10 at 4:48 PM logoFTSE 100 drops as home builders fall on gloomy price data - August 10 at 5:27 AM logoEuropean Stocks Set For Mixed Open as Global Markets Stabilize Despite North Korea Concerns - August 10 at 5:27 AM
News IconUPDATE 1-US FDA panel votes against approval of J&J arthritis drug - Business Insider - August 3 at 2:45 AM logoGlaxoSmithKline’s 2Q17 Earnings: Vaccines Business - August 2 at 4:27 PM logoGSK’s 2Q17 Earnings: Consumer Healthcare - August 2 at 4:27 PM logo[$$] Novartis faces vexing decisions over asset sales - August 2 at 12:49 AM logoGlaxoSmithKline Plc :GSK-GB: Earnings Analysis: Q2, 2017 By the Numbers : August 1, 2017 - July 31 at 11:53 PM logoShore Capital Reiterates Hold Rating for GlaxoSmithKline plc (GSK) - July 29 at 11:16 PM logoGlaxoSmithKline plc (GSK) Receives Consensus Recommendation of "Hold" from Brokerages - July 29 at 7:48 AM logoEdited Transcript of GSK.L earnings conference call or presentation 26-Jul-17 1:00pm GMT - July 28 at 12:50 AM logoMorgan Stanley Analysts Give GlaxoSmithKline plc (LON:GSK) a GBX 1,700 Price Target - July 27 at 1:14 PM logoGlaxoSmithKline plc's (LON:GSK) Neutral Rating Reaffirmed at Credit Suisse Group - July 27 at 10:35 AM logoGlaxo (GSK) Beats Q2 Earnings, Misses Sales - Nasdaq - July 27 at 12:53 AM logoGlaxoSmithKline plc (LON:GSK) Given a GBX 1,500 Price Target at S&P Global - July 26 at 6:17 PM logoGlaxoSmithKline plc to Issue Dividend of GBX 19 (LON:GSK) - July 26 at 4:31 PM logoGlaxoSmithKline plc (GSK) Insider Acquires £36,249.33 in Stock - July 26 at 1:15 PM logoGlaxoSmithKline Names Former Walmart Exec as New CTO - - July 25 at 7:34 PM logoTOP NEWS: GlaxoSmithKline Data Shows Tolerability For HIV Regimen - July 24 at 8:53 AM logoGlaxoSmithKline: ViiV Healthcare Presents 96-week Data From LATTE-2 Study - July 24 at 8:53 AM


Social activity is not available for this stock.


GlaxoSmithKline plc (GSK) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff